The proportion of myeloma cases linked to BMI and diabetes was higher in Black patients than White patients. Patients who were Black or female were more likely to refuse treatment for multiple myeloma. The study looked at disparities in outcomes of infusion with ide-cel or cilta-cel in patients with relapsed or refractory MM. Significant delays in diagnosing multiple myeloma exist. Talquetamab is a promising treatment for relapsed multiple myeloma, however, it presents unique side effects. In MM patients, prescription delays were linked to Black race, older age, inpatient diagnosis, and severe renal impairment. There is a disproportionately high MM incidence and mortality among non-Hispanic Black Americans. Dr. Ailawadhi explores ways that researchers are designing trials to address racial disparities in enrollment. Dr. Ailawadhi explained how oncologists should consider racial differences when approaching clinical care. Inpatient treatment comprised 48% of medical costs in patients with renal impairment. Patients with multiple myeloma in the US Military Health System had significantly better survival rates. Race was associated with the dollar amount patients were willing to pay for treatment each month. Obesity significantly increases the risk of multiple myeloma, especially in Black populations. These factors may drive disparities in care for Black patients with multiple myeloma. A new study shows why it's important for nurses to be aware of how social determinants of health affect medication adherence. It's important for nurses to recognize opportunities to address racial disparities in hospice use and access. Clinical trial knowledge is related to the likelihood of participation. More than 70% of patients aged 70 years and older with multiple myeloma prioritized functional independence as important. Stem cell transplant utilization remains suboptimal and marked by racial-ethnic disparities. The study results underscore the importance of equitable treatment access for all patients.